NEW

New Version of c.cam Cardiac SPECT System Debuts in U.S.

Siemens Healthineers has introduced a new version of its c.cam dedicated cardiac nuclear medicine system to the U.S. market. This single-photon emission computed tomography (SPECT) scanner with a reclining patient chair offers nuclear cardiology providers a low total...

Physicians Highlight Potential of Radiopharmaceuticals in Oncology

The Medical Imaging & Technology Alliance (MITA), along with the Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR) and the Society of Nuclear Medicine & Molecular Imaging (SNMMI), hosted a virtual briefing for Capitol Hill staff this month with...

Nanox Signs Agreement to Deploy 630 Units in Mexico

NANO-X IMAGING LTD, an innovative medical imaging technology company, announced that it has entered into an exclusive distribution agreement with SPI Medical (SPI) for the deployment and introduction of Nanox’s medical imaging services in Mexico. SPI Medical, S. A. P....

Inaugural ICE Webinar Delivers ‘Pertinent’ Information

The Imaging Community Exchange (ICE) magazine continues to grow and part of the growth is a brand-new webinar series where imaging leaders can earn valuable continuing education (CE) credits. The webinar series, dubbed “A cool series for hot topics,” began Tuesday...

GE Healthcare Pristina Serena Bright

Typically lesions identified with contrast enhanced mammography are sent to MRI for biopsy, but now with Pristina Serena Bright, the industry-first contrasted enhanced-guide biopsy solution, breast biopsy exams can now be performed with the same mammography equipment, with the same staff, and in the same room as the screening or diagnostic mammogram.

When compared to MRI-guided breast biopsy, the potential benefits of contrast enhanced-guided biopsy include shortened procedure time, improved patient comfort and reduced cost for patients.

Key to this this technology’s application is GE Healthcare’s SenoBright HD Contrast Enhanced Spectral Mammography (CESM), a diagnostic imaging tool that delivers high sensitivity for more accurate breast cancer diagnosis. By highlighting areas of unusual blood flow to help localize lesions that need to be biopsied, CESM biopsy – Serena Bright – helps improve radiologists’ diagnostic confidence with the goal of getting answers to patients as quickly as possible. •Pristina Serena Bright will be commercially available in the United States in October 2020.

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *